TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07037862: A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability

Sponsor: Entrada Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$525,300

Rescue Site Savings

+$350,200

Unlock Full NCT07037862 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07037862 Rescue Dossier →